mixture was allowed to cool to room temperature. The aqueous layer was separated and neutralized with aqueous NaOH. The aqueous layer was extracted with EtOAc (3 × 10 mL). The organic layers were combined and concentrated. The residue was purified on a Combiflash purification system using a silica flash column (90:10 CH2Cl2/MeOH) to afford the quinoline substrate.
General procedure I (synthesis of noncommercial substituted piperazines): 2 To a solution of N-Boc-piperazine (1 equiv) in toluene (1.5 mL) were added the appropriate bromo-substituted heterocyle (1 equiv), Pd2(dba)3 (2 mole %), (±)-BINAP (4 mole %) and NaO t Bu (1.5 equiv). The reaction mixture was stirred at 70 ˚C for 90 mins.
The mixture filtered through celite, washed with EtOAc and evaporated under reduced pressure. The residue was purified on a medium-pressure chromatography purification system using a silica flash column (80:20 Hexanes/EtOAc) to afford the Boc-protected product. To boc-protected compound in CH2Cl2 (1.5 mL) was added TFA (1.5 mL) and resulting mixture was stirred for 1 h. The solvent was evaporated under reduced pressure to afford the unprotected piperazine, which was used for next reaction without further purification. 2, 152.0, 149.5, 148.1, 139.7, 137.8, 133.1, 127.8, 126.3, 122.3, 120.4, 113.9, 107.3, 52.7, 45.1, 41.2; IR (neat) (2) . This compound was synthesized during our previous work on this series. 89-91 ˚C; TLC (5% MeOH/CH2Cl2): Rf = 0.6; 1 H NMR (500 MHz, CDCl3) δ 8.89 (dd, J = 4.2, 1.6 Hz, 1H), 8.45 (dd, J = 8.5, 1.6 Hz, 1H), 1H), 7.63 (s, 1H), 2H), 2H), 3.94 (s, 2H) , 3.66 (t, J = 4.9 Hz, 4H), 2.84 -2.71 (m, 4H); 13 C NMR (126 MHz, CDCl3) δ 159. 2, 152.7, 149.5, 148.1, 139.9, 137.8, 135.6, 131.4, 127.5, 122.7, 113.9, 109.9, 107.3, 52.7, 45.1, 41.2; IR (neat) (4) . To a solution of 5-chloro-7-((4-(pyridin-2-yl)piperazin-1-yl)methyl)quinolin-8-ol (0.0500 g, 0.140 mmol, 1 equiv) in DMF (5 mL), was added NaH (60% dispersion in mineral oil, 0.0085 g, 0.210 mmol, 1.5 equiv) at 0 ˚C and stirred for 30 mins. Then, methyl iodide (0.060 g, 0.420 mmol, 3 equiv) was added to reaction mixture at 0 ˚C and the mixture was further stirred at rt for 4 h. The mixture was quenched by adding H2O (10 mL). The aqueous layer was extracted with EtOAc (3 × 10 mL). The organic layers were combined and concentrated. The crude product was purified by mass directed HPLC to afford 4 (0.0152 g, 26%) as an orange solid. Mp: 118-120 ˚C; TLC (5% MeOH/CH2Cl2): Rf = 0.6; 1 H NMR (500 MHz, CDCl3) δ 8.98 (dd, J = 4.2, 1.7 Hz, 1H), 8.55 (dd, J = 8.5, 1.7 Hz, 1H), 8.19 (ddd, J = 5.0, 2.1, 0.9 Hz, 1H), 7.82 (s, 1H), 7.55 -7.44 (m, 2H), 6.68 -6.59 (m, 2H) , 4.13 (s, 3H), 3.82 (s, 2H), 3.58 (s, 4H), 2.66 (s, 4H); 13 C NMR (126 MHz, CDCl3) δ 153. 7, 150.2, 148.1, 143.5, 137.6, 133.4, 128.5, 127.0, 126.1, 121.9, 113.4, 107.3, 63.0, 56.1, 53.1, 45.4; IR (neat) 7, 144.9, 140.1, 133.8, 133.2, 130.5, 126.7, 126.0, 122.6, 62.6; IR (neat) 6, 151.5, 148.1, 145.3, 138.2, 137.7, 133.6, 131.7, 130.1, 128.0, 126.6, 122.5, 113.5, 107.3, 59.5, 53.2, 45.4; IR (neat) 373.0987, found: 373.0977; HPLC purity = 93.6%.
5-Chloro-7-((4-(pyridin-2-yl)piperazin-1-yl)methyl)quinolin-8-ol

7-((4-(Pyridin-2-yl)piperazin-1-yl)methyl)quinolin-8-ol
5-Chloro-8-methoxy-7-((4-(pyridin-2-yl)piperazin-1-yl)methyl)quinolone
5-Chloro-2-methyl-3-nitrobenzoic acid (S-6''): To 5-chloro-2-methylbenzoic acid (0.412 g, 2.21 mmol, 1 equiv) in H2SO4 was dropwise added mixture HNO3 and H2SO4 at 0 ˚C. The resulting mixture was brought to room temperature and further stirred for 7 h.
To the mixture ice cold water was added and the resulting precipitate was filtered. The precipitate was purified on a Combiflash purification system using a silica flash column 6, 149.8, 148.2, 148.1, 137.6, 135.3, 133.1, 128.5, 125.5, 121.4, 113.4, 107.2, 60.4, 53.2, 45.4, 13 2, 144.4, 139.9, 136.6, 130.8, 128.8, 126.7, 126.3, 121.9, 63.1; IR (neat) 8-Chloro-7-((4-(pyridin-2-yl)piperazin-1-yl)methyl)quinoline (7) . Triethylamine (0.048, 0.475 mmol, 1.5 equiv), (8-chloroquinolin-7-yl) 1, 148.0, 144.8, 137.7, 136.5, 132.9, 128.5, 126.3, 121.8, 113.5, 111.9, 107.3, 59.7, 53.2, 45.3; IR (neat) 6, 147.3, 139.2, 136.4, 134.5, 127.7, 126.5, 125.7, 120.9, 63.7, 12.7; IR (neat) 4, 149.4, 148.0, 147.6, 137.7, 136.3, 129.0, 127.7, 125.3, 120.9, 118.0, 115.7, 113.5, 107.3, 60.6, 53.0, 45.1, 13.4; IR (neat) 1, 137.6, 136.1, 131.0, 127.4, 124.6, 121.8, 120.5, 113.4, 112.0, 107.2, 102.6, 63.7, 52.9, 45.1; IR (neat) ( 1, 137.7, 136.3, 135.1, 128.4, 121.9, 120.3, 119.8, 113.6, 110.9, 107.3, 102.1, 56.0, 53.1, 45.2; IR (neat) 
6-((4-(Pyridin-2-yl)piperazin-1-yl)methyl)-1H-indole (9). (1H-indol-6-yl)(4-(pyridin-
2-((4-(Pyridin-2-yl)piperazin-1-yl)methyl)-1H-indole
1-(Naphthalen-2-ylmethyl)-4-(pyridin-2-yl)piperazine (11):
This compound was synthesized as previously described. 3 HPLC purity = 98.1%. 2, 135.5, 129.4, 129.0, 126.4, 120.7, 119.0, 114.0, 111.1, 107.7, 102.9, 100.1, 45.8; IR (neat) 7, 159.1, 148.2, 137.9, 135.8, 129.3, 127.7, 124.7, 122.1, 120.8, 114.0, 111.9, 107.3, 105.6, 45.3 7, 149.4, 146.8, 141.2, 139.6, 138.9, 133.1, 127.9, 126.2, 123.7, 122.8, 122.4, 120.4, 118.1, 59.1, 52.6, 48.6; IR (neat) 2, 152.0, 149.5, 148.1, 139.7, 137.8, 133.1, 127.8, 126.3, 122.3, 120.4, 113.9 6, 157.9, 152.0, 149.5, 139.7, 133.0, 127.8, 126.2, 122.3, 120.3, 110.4, 59.6, 52.8, 43.6; IR (neat) 6, 149.4, 146.0, 145.9, 145.9, 145.8, 139.5, 134.8, 134.8, 134.8, 134.7, 133.1, 128.0, 126.2, 125.7, 123.6, 122.4, 120.4, 115.8, 115.5, 105.8, 58.9, 52.6, 44.7, 29.9; IR (neat) 8, 153.7, 141.2, 136.7, 129.4, 80.4, 44.7, 28.5 
1-(
5-Chloro-7-((4-(pyrazin-2-yl)piperazin-1-yl)methyl)quinolin-8-ol
5-Chloro-7-((4-phenylpiperazin-1-yl)methyl)quinolin-8-ol (23). This compound was
purchased (Enamine Ltd.) during our previous work on this series. 6, 141.4, 139.1, 136.1, 128.0, 125.3, 123.7, 122.9, 122.0, 120.8, 112.9, 103.6, 102.6, 63.1, 52.3, 47.8; HRMS (ESI) 6, 146.7, 141.7, 139.2, 135.9, 129.1, 127.6, 124.8, 123.8, 123.0, 122.1, 120.9, 111.9, 105.6, 54.5, 49.0; IR (neat) 6, 141.4, 139.0, 136.6, 128.1, 123.7, 122.9, 122.3, 120.5, 120.0, 111.2, 103.1, 55.6, 52.7, 48 138.5, 133.4, 133.2, 128.7, 128.5, 127.9, 127.8, 127.6, 126.4, 126.3, 123.8, 123.0, 62 1, 140.0, 137.9, 134.0, 132.6, 128.7, 128.6, 128.2, 126.2, 125.9, 125.3, 124.6, 123.9, 122.9, 60.8, 52.9, 48.3; IR (neat) 2, 149.7, 149.4, 147.6, 136.7, 136.3, 136.2, 128.9, 127.6, 125.1, 120.8, 108.4, 60.9, 52.8, 46.2, 13.2; IR ( (m, 4H); 13 C NMR (101 MHz, CDCl3) δ 162. 7, 154.6, 150.6, 135.9, 128.9, 127.7, 124.9, 122.1, 121.0, 111.9, 108.5, 105.7, 60.5, 45.9; IR (neat) 1, 161.5, 157.9, 155.1, 135.5, 129.6, 128.6, 126.5, 120.8, 119. 3, 158.4, 155.7, 136.1, 127.6, 124.9, 121.8, 121.2, 120.7, 112.2, 103.1, 102.7, 63.5, 52.5, 43.4; HRMS (ESI) NMR (400 MHz, CDCl3) δ 9.60 (s, 1H), 8.66 (s, 1H), 8.28 (d, J = 6.2 Hz, 1H), 7.67 (dd, J = 8.0, 1.1 Hz, 1H), 7.45 (dd, J = 8.3, 1.0 Hz, 1H), 7.30 (ddd, J = 8.2, 7.0, 1.1 Hz, 1H), 7.15 (ddd, J = 8.0, 6.9, 1.0 Hz, 1H), 6.83 (dd, J = 2.2, 0.9 Hz, 1H), 6.54 (dd, J = 6.3, 1.2 Hz, 1H), 4.08 (s, 4H), 3.92 -3.71 (m, 4H) ; 13 C NMR (101 MHz, CDCl3) δ 162.9, 161.4, 158.5, 156.1, 135.9, 128.9, 127.6, 124.9, 122.1, 120.9, 111.9, 105.8, 103.1, 43.5; IR (neat) 4, 158.5, 155.8, 136.4, 134.5, 128.3, 122.0, 120.4, 119.9, 111.0, 103.1, 102.4, 55.9, 52.7, 43.6; IR (neat) 1, 153.7, 150.2, 149.4, 143.5, 141.9, 133.4, 133.1, 131.2, 128.4, 127.0, 126.1, 122.0, 63.0, 56.1, 52.9, 44.6; IR (neat) 2837, 1575 cm 1, 151.6, 145.3, 141.9, 137.9, 133.6, 133.2, 131.8, 131.2, 130.1, 128.0, 126.7, 122.5, 59.4, 53.0, 44.7; IR (neat) 4, 147.6, 141.9, 136.9, 136.3, 136.2, 133.0, 131.2, 128.9, 127.6, 125.1, 120.7, 61.0, 52.9, 44.7, 13.2; IR (neat) 141.9, 135.6, 133.5, 133.0, 133.0, 131.2, 128.2, 127.8, 127.8, 127.5, 126.2, 125.9, 63.4, 52.9, 44.7; IR (neat) 1, 148.0, 144.8, 137.7, 136.5, 132.9, 128.5, 126.3, 121.8, 113.5, 111.9, 107.3, 59.7, 53.2, 45.3; IR (neat) 8, 157.9, 151.5, 145.3, 138.2, 133.6, 131.8, 130.1, 128.1, 126.6, 122.5, 110.0, 59.5, 53.3, 43.9; IR (neat) HPLC purity > 99.8%. 8, 157.9, 149.8, 148.2, 137.5, 135.3, 133.1, 128.5, 125.5, 121.4, 110.0, 105.2, 60.5, 53.3, 43.9, 13.2; IR (neat) 6, 157.9, 149.5, 147.5, 139.2, 136.4, 129.0, 127.8, 125.4, 121.0, 110.2, 53.0, 41.1, 29.9, 13.4; IR (neat) 
6-((4-(Pyridin-3-yl)piperazin-1-yl)methyl)-1H-indole (25): (1H-indol-6-yl)(4-(pyridin-
2-((4-(Pyridin-3-yl)piperazin-1-yl)methyl)-1H-indole (26): (1H-indol-2-yl)(4-(pyridin-
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